Bristol-Myers Squibb announced a strategic partnership with Anthropic to deploy advanced AI capabilities across its operations, focusing on drug discovery and development in oncology and neuroscience. The collaboration will leverage AI, multimodal data, and Tempus' analytical platform to streamline research, clinical development, and manufacturing processes, aiming to improve trial design and patient population identification.

Ventripoint Diagnostics has achieved multiple validation milestones in early 2026, including submitting its VMS+ 4.0 system to China's NMPA for expedited review, exhibiting at Europe's largest congenital cardiology conference, and establishing commercial partnerships for hospital deployment. The company is capitalizing on a shifting procurement environment where hospitals now demand economic proof alongside clinical accuracy for AI cardiac imaging solutions.

Tempus AI and Bristol Myers Squibb announced an expanded collaboration to use AI and real-world data to improve clinical trial design across oncology and neuroscience programs. The partnership leverages Tempus' Lens platform to analyze patient records and aims to strengthen drug development strategies, identify appropriate patient populations, and accelerate treatment delivery, building on their existing Next Pathways program.

The healthcare industry is shifting toward data-driven, precision medicine models powered by AI and genomic data. Three companies are positioned to lead this transformation: Tempus AI is building a healthcare data platform with network effects; Recursion Pharmaceuticals is accelerating drug discovery through automation and machine learning; and Axsome Therapeutics is gaining traction with fast-acting CNS treatments, particularly its antidepressant Auvelity.

Pathos AI announced the acquisition of a majority stake in Belgium-based DeuterOncology, which is developing DO-2, a third-generation MET kinase inhibitor for MET-altered cancers. The asset was identified through Pathos's Foundry AI platform. DO-2 demonstrated 100% tumor shrinkage in Phase 1 trials with a superior safety profile and significantly lower peripheral edema rates (5%) compared to competitors (62-82%), with patent exclusivity extending to December 2040.

The AI clinical trial protocol feasibility tool market is experiencing rapid expansion, growing from $0.83 billion in 2025 to $1.06 billion in 2026 with a 27.3% CAGR. The market is projected to reach $2.76 billion by 2030, driven by increasing protocol complexity, precision medicine focus, decentralized trial designs, and AI-enabled protocol optimization. Key players include IQVIA Holdings, SAS Institute, Veeva Systems, and Tempus AI, with North America leading and Asia-Pacific emerging as the fastest-growing region.

A wave of momentum swept through large-cap stocks during the week of April 13-17, 2026, with ten standout performers. Notable gainers include Avis Budget Group (71.48% jump driven by short squeeze), IonQ (62.86% surge following DARPA contract award), Oklo (33.35% rise on nuclear power narrative), Robinhood (33.22% gain from bullish analyst outlook and crypto rebound), and Strategy Inc (31.86% increase). Other top performers include Tempus AI, Credo Technology, Affirm Holdings, and Summit Therapeutics, with gains ranging from 28-31%.

Tempus AI (NASDAQ: TEM) shares rose 7.30% to $49.34 following the announcement that 31 abstracts were accepted for presentation at the AACR Annual Meeting 2026. The presentations highlight emerging biomarkers and real-world evidence in cancer treatment, including studies on MSI-related gene fusions in colorectal cancer, KMT2C mutations linked to platinum therapy benefits, and SCLC subtype variability. However, Jefferies initiated coverage with an Underperform rating and $35 price target.

Tempus AI announced an expanded multi-year collaboration with Merck to accelerate AI-driven precision medicine development. The partnership will leverage Tempus' data library and Lens Platform to identify novel precision biomarkers for oncology and other therapeutic areas. Despite the positive deal announcement, Tempus shares declined 1.56% amid broader market sell-offs affecting the S&P 500 and Nasdaq.

Hospital networks are increasingly adopting AI-enhanced cardiac imaging technologies to reduce costs and improve patient outcomes. The AI medical imaging market is projected to reach nearly $20 billion by 2033, with echocardiography expected to grow to $2.64 billion by 2030. Key players including VentriPoint Diagnostics, Butterfly Network, Tempus AI, RadNet, and GE HealthCare are expanding their deployments across healthcare systems, with several reporting strong revenue growth and positive financial metrics.

The week saw escalating US-Taiwan trade tensions following the Supreme Court's strike-down of Trump's emergency tariff authority, prompting new tariff rollouts. Major tech companies reported mixed earnings results, with Amazon announcing a $12B US investment and Apple shifting Mac Mini production to Texas. AI developments dominated headlines with OpenAI's Frontier Alliances program, Microsoft's Sovereign Cloud expansion, and concerns over Chinese AI capabilities. The EV market showed growth with new models from Tesla competitors, while several companies announced restructuring efforts.

Cathie Wood's Ark Invest added to positions in AMD, Tesla, and Tempus AI on Wednesday amid market volatility. AMD delivered strong earnings with 34% revenue growth and beat profit expectations, but shares fell 17% due to disappointing guidance. Tesla is pivoting toward robotics production as EV sales stall. Tempus AI, focused on oncology AI solutions, has seen shares cut in half from October highs despite 84% revenue growth.